Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

ZNF217 is a candidate oncogene with a wide variety of deleterious functions in breast cancer. Here, we aimed at investigating in a pilot prospective study the association between ZNF217 mRNA expression levels and the clinical response to neoadjuvant endocrine therapy (ET) in postmenopausal ER-positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vendrell, Julie A., Solassol, Jérôme, Győrffy, Balázs, Vilquin, Paul, Jarlier, Marta, Donini, Caterina F., Gamba, Laurent, Maudelonde, Thierry, Rouanet, Philippe, Cohen, Pascale A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355665/
https://www.ncbi.nlm.nih.gov/pubmed/30740056
http://dx.doi.org/10.3389/fphar.2018.01581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355665/
https://www.ncbi.nlm.nih.gov/pubmed/30740056
http://dx.doi.org/10.3389/fphar.2018.01581

Ejemplares similares